Efficacy and tolerability of topical foscarnet sodium in treatment of herpes labialis. Results of post-marketing surveillance

被引:0
作者
Gross, G
Braun, D
机构
[1] Univ Rostock, Univ Klin & Poliklin Dermatol & Venerol, D-18055 Rostock, Germany
[2] Riemser Arzneimittel AG, Greifswald, Germany
来源
HAUTARZT | 2006年 / 57卷 / 01期
关键词
recurrent herpes labialis; foscarnet sodium cream; post-marketing surveillance; efficacy; tolerability;
D O I
10.1007/s00105-005-1041-3
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background and Objective. Aim of this post-marketing surveillance study was to generate further data on efficacy and tolerability of foscarnet sodium cream 2% in patients with recurrent herpes labialis in daily routine practice. Design and Methods. 90 outpatients with recurrent herpes labialis were instructed to apply the antiviral cream to the lesions according to package insert for up to 10 days. Symptoms were recorded before beginning of treatment, after three days, and at the end of treatment. Results. Paresthesia and swelling as well as the number of vesicles were reduced after three days of observation, and were improved by about 90% at the end of treatment. Erosions and crust formation also improved markedly. Efficacy as well as tolerability were evaluated as positive by the majority of physicians and patients. No adverse reactions were reported. Conclusions. Foscarnet sodium 2% cream is an effective and safe medication for the treatment of recurrent labial herpes in daily routine practice of dermatologists.
引用
收藏
页码:40 / 46
页数:9
相关论文
共 19 条
[1]   THERAPEUTIC EFFECTS OF FOSCARNET SODIUM AND ACYCLOVIR ON CUTANEOUS INFECTIONS DUE TO HERPES-SIMPLEX VIRUS TYPE-1 IN GUINEA-PIGS [J].
ALENIUS, S ;
BERG, M ;
BROBERG, F ;
EKLIND, K ;
LINDBORG, B ;
OBERG, B .
JOURNAL OF INFECTIOUS DISEASES, 1982, 145 (04) :569-573
[2]   Antiviral drugs [J].
Balfour, HH .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (16) :1255-1268
[3]  
BARTON SE, 1986, GENITOURIN MED, V62, P247
[4]   Effect of foscarnet cream on experimental UV radiation-induced herpes labialis [J].
Bernstein, DI ;
Schleupner, CJ ;
Evans, TG ;
Blumberg, DA ;
Bryson, Y ;
Grafford, K ;
Broberg, P ;
MartinMunley, S ;
Spruance, SL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) :1961-1964
[5]  
EMBIL JA, 1975, CAN MED ASSOC J, V113, P627
[6]   ACYCLOVIR-RESISTANT HERPES-SIMPLEX VIRUS-INFECTIONS IN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME [J].
ERLICH, KS ;
MILLS, J ;
CHATIS, P ;
MERTZ, GJ ;
BUSCH, DF ;
FOLLANSBEE, SE ;
GRANT, RM ;
CRUMPACKER, CS .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (05) :293-296
[7]   Herpes simplex virus infections [J].
Gross G. .
Der Hautarzt, 2004, 55 (9) :818-830
[8]  
GROSS G, 1996, CHEMOTHERAPIE J S10, V5, P24
[9]  
GROSS G, 1995, BRAUN FACHVERLAGE, V39, pS41
[10]   Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: A phase I/II study [J].
Javaly, K ;
Wohlfeiler, M ;
Kalayjian, R ;
Klein, T ;
Bryson, Y ;
Grafford, K ;
Martin-Munley, S ;
Hardy, WD .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (04) :301-306